CTIS2023-505650-17-00进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (age 12 years to < 18 years) with Symptomatic Obstructive Hypertrophic Cardiomyopathy - CV027-010
Bristol-Myers Squibb Services Unlimited Company0 个研究点目标入组 40 人开始时间: 2024年1月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Adolescents aged 12 to <18 at the time of agreeing to participate, Diagnosis of HCM, Presence of LVOT obstruction, Presence of symptoms
排除标准
- •Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction, Evidence of LVEF <50% in prior 6 months, Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)
研究者
相似试验
招募中
1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with CardiomyopathyEUCTR2021-005329-26-NLMyokardia, Inc.420
招募中
3 期
Mavacamten in non-obstructive HCMsymptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)JPRN-jRCT2051220175Aronson Ron34
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with CardiomyopathyEUCTR2021-005329-26-NOMyokardia, Inc.420
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with CardiomyopathySymptomatic Nonobstructive Hypertrophic CardiomyopathyMedDRA version: 20.0Level: PTClassification code 10049813Term: Non-obstructive cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-005329-26-DEMyokardia, Inc.420
招募中
3 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic CardiomyopathyNL-OMON56426Myokardia, Inc.31